| Title： | Experts consensus on Adverse Drug Reactions Management of PAPR Inhibitors |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | |
| Evidence classification method： | Expert discussion method |
| Development unit： | Committee of Clinical Pharmacyon Oncology, Zhejiang Anticancer Association (preparation) |
| Registration time: | 2022-10-29 |
| Registration number： | PREPARE-2022CN696 |
| Purpose of the guideline: |
